EMA
approval
· 2026-07-08
EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)
Summary
EU authorization of Altuvoct (efanesoctocog alfa) for Hemophilia A.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 03/07/2026. Orphan medicine